Company Monitoring Page for Alnylam-Pharmaceuticals

latest headlines for company on cafepharma

Alnylam reveals trial outcomes of nucresiran for ATTR amyloidosis treatment
Clinical Trials Arena
Mon, 11/18/24 - 06:30 pm
Tags:
Alnylam Pharmaceuticals, nucresiran, RNAi, clinical trials
An RNAi renaissance is creating a new generation of startups
BioPharma Dive
Wed, 11/6/24 - 11:41 am
Tags:
RNAi, Alnylam Pharmaceuticals, City Therapeutics, Jude Bio, Switch Therapeutics, Aro Biotherapeutics
Full study data back Alnylam heart drug’s benefit, but leave doctors with tough choices
BioPharma Dive
Fri, 08/30/24 - 11:20 am
Tags:
Alnylam Pharmaceuticals, transthyretin amyloidosis cardiomyopathy
Roche, Alnylam say blood pressure drug succeeds in mid-stage trial
Reuters
Tue, 03/5/24 - 11:07 am
Tags:
Roche, Alnylam Pharmaceuticals, clinical trials, hypertension, zilebesiran
10 clinical trials to watch in the first half of 2024
BioPharma Dive
Wed, 01/3/24 - 05:08 pm
Tags:
clinical trials, Beam Therapeutics, Moderna Therapeutics, Pfizer, Sanofi, Gilead Sciences, JNJ, Amylx, Roche, Alnylam Pharmaceuticals, Vertex Pharmaceuticals
Alnylam sticks with aggressive litigation strategy against Pfizer and Moderna, filing yet another patent lawsuit
Fierce Pharma
Tue, 05/30/23 - 09:28 pm
Tags:
Alnylam Pharmaceuticals, legal, patents, vaccines, Pfizer, Moderna Therapeutics, COVID-19
Alnylam’s Onpattro succeeds in open-label ATTR cardiomyopathy extension
Clinical Trials Arena
Mon, 05/22/23 - 10:11 am
Tags:
Alnylam Pharmaceuticals, Onpattro, clinical trials, transthyretin amyloidosis with cardiomyopathy
Biotech heads towards big catalysts
EP Vantage
Tue, 03/28/23 - 10:24 am
Tags:
biotech, clinical trials, Alnylam Pharmaceuticals, Arcus Biosciences, Argenx, Arrowhead Pharmaceuticals, Axsome Therapeutics, Bavarian Nordic, FibroGen, Gilead Sciences, Incyte, Morphic Therapeutic, PTC Therapeutics, Syndax Pharmaceuticals, Travere Therapeutics, Vaxcyte
Brace for an end-of-year boost to drug approvals
EP Vantage
Fri, 09/2/22 - 12:14 pm
Tags:
FDA, drug approvals, Alnylam Pharmaceuticals, Apellis Pharmaceuticals, Bristol Myers Squibb, Eli Lilly, Gilead Sciences, Mirati Therapeutics, Moderna Therapeutics, Provention Bio, Roche, TG Therapeutics, Travere Therapeutics
Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
Businesswire
Mon, 08/29/22 - 10:26 am
Tags:
Alnylam Pharmaceuticals, clinical trials, cemdisiran, Regeneron, IgAN, immunoglobultin A nephropathy, RNAi
11 drugs granted FDA fast track designation in 2022
Beckers Hospital Review
Wed, 08/24/22 - 10:55 pm
Tags:
FDA, fast track, Agios Pharmaceuticals, CTI BioPharma, Bristol Myers Squibb, Nobel Biocare, BioXcel Therapeutics, Mycovia Pharmaceuticals, Phathom Pharmaceuticals, Mitsubishi Tanabe Pharma, SIGA technologies, Alnylam Pharmaceuticals
3 Biopharmas on Buyout Watch
Motley Fool
Mon, 08/22/22 - 10:39 am
Tags:
M&A, Axsome Therapeutics, Alnylam Pharmaceuticals, Karuna Therapeutics
Drugmakers leap back into fading heart drug market
Beckers Hospital Review
Thu, 07/28/22 - 06:40 pm
Tags:
Bristol Myers Squibb, Novartis, Merck, Alnylam Pharmaceuticals, Amgen, hypertension, cholesterol
Alnylam sues Pfizer, Moderna over patent used in mRNA COVID vaccines
Seeking Alpha
Thu, 03/17/22 - 10:14 am
Tags:
Alnylam Pharmaceuticals, patents, COVID-19, vaccines, Pfizer, Moderna Therapeutics, MRNA
Novartis turns to Alnylam in research deal aimed at liver failure
BioPharma Dive
Thu, 01/6/22 - 10:57 am
Tags:
Novartis, Alnylam Pharmaceuticals, liver failure
Biopharma developments over the Christmas period
EP Vantage
Mon, 01/3/22 - 10:26 am
Tags:
Alnylam Pharmaceuticals, Bio-Thera Solutions, BioArctic, Biogen, BridgeBio Pharma, Daiichi Sankyo, Eisai, JNJ, Madrigal Pharmaceuticals, Merck, Sutro BioPharma, Tasly Pharmaceutical Group

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.